Literature DB >> 12234864

Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives.

Wim Pluymers1, Godwin Pais, Bénédicte Van Maele, Christophe Pannecouque, Valery Fikkert, Terrence R Burke, Erik De Clercq, Myriam Witvrouw, Nouri Neamati, Zeger Debyser.   

Abstract

A series of diketo derivatives was found to inhibit human immunodeficiency virus type 1 (HIV-1) integrase activity. Only L-708,906 inhibited the replication of HIV-1(III(B)) (50% effective concentration, 12 micro M), HIV-1 clinical strains, HIV-1 strains resistant to reverse transcriptase or fusion inhibitors, HIV-2 (ROD strain) and simian immunodeficiency virus (MAC(251)). The combinations of L-708,906 with zidovudine, nevirapine, or nelfinavir proved to be subsynergistic. In cell culture, addition of L-708,906 could be postponed for 7 h after infection, a moment coinciding with HIV integration. Inhibition of integration in cell culture was confirmed by quantitative Alu-PCR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234864      PMCID: PMC128766          DOI: 10.1128/AAC.46.10.3292-3297.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Assays for the evaluation of HIV-1 integrase inhibitors.

Authors:  Z Debyser; P Cherepanov; W Pluymers; E De Clercq
Journal:  Methods Mol Biol       Date:  2001

Review 2.  Retroviral integrase inhibitors year 2000: update and perspectives.

Authors:  Y Pommier; C Marchand; N Neamati
Journal:  Antiviral Res       Date:  2000-09       Impact factor: 5.970

3.  Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.

Authors:  J A Este; D Schols; K De Vreese; K Van Laethem; A M Vandamme; J Desmyter; E De Clercq
Journal:  Mol Pharmacol       Date:  1997-07       Impact factor: 4.436

Review 4.  Integration of retroviral DNA.

Authors:  P O Brown
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

5.  Structural determinants for HIV-1 integrase inhibition by beta-diketo acids.

Authors:  Christophe Marchand; Xuechun Zhang; Godwin C G Pais; Kiriana Cowansage; Nouri Neamati; Terrence R Burke; Yves Pommier
Journal:  J Biol Chem       Date:  2002-01-22       Impact factor: 5.157

6.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

Authors:  C M Farnet; B Wang; J R Lipford; F D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

7.  Integration of human immunodeficiency virus type 1 DNA in vitro.

Authors:  C M Farnet; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

8.  Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity.

Authors:  P A Sherman; J A Fyfe
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

9.  Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells.

Authors:  R L LaFemina; C L Schneider; H L Robbins; P L Callahan; K LeGrow; E Roth; W A Schleif; E A Emini
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

Review 10.  In search of authentic inhibitors of HIV-1 integration.

Authors:  Zeger Debyser; Peter Cherepanov; Bénédicte Van Maele; Erik De Clercq; Myriam Witvrouw
Journal:  Antivir Chem Chemother       Date:  2002-01
View more
  8 in total

1.  Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction.

Authors:  Bénédicte Van Maele; Jan De Rijck; Erik De Clercq; Zeger Debyser
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.

Authors:  Valery Fikkert; Bénédicte Van Maele; Jo Vercammen; Anke Hantson; Barbara Van Remoortel; Martine Michiels; Cristina Gurnari; Christophe Pannecouque; Marc De Maeyer; Yves Engelborghs; Erik De Clercq; Zeger Debyser; Myriam Witvrouw
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

Authors:  Daria J Hazuda; Neville J Anthony; Robert P Gomez; Samson M Jolly; John S Wai; Linghang Zhuang; Thorsten E Fisher; Mark Embrey; James P Guare; Melissa S Egbertson; Joseph P Vacca; Joel R Huff; Peter J Felock; Marc V Witmer; Kara A Stillmock; Robert Danovich; Jay Grobler; Michael D Miller; Amy S Espeseth; Lixia Jin; I-Wu Chen; Jiunn H Lin; Kelem Kassahun; Joan D Ellis; Bradley K Wong; Wei Xu; Paul G Pearson; William A Schleif; Riccardo Cortese; Emilio Emini; Vincenzo Summa; M Katharine Holloway; Steven D Young
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

4.  Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.

Authors:  Katty Terrazas-Aranda; Yven Van Herrewege; Daria Hazuda; Paul Lewi; Roberta Costi; Roberto Di Santo; Andrea Cara; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

5.  Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.

Authors:  Signe Fransen; Soumi Gupta; Robert Danovich; Daria Hazuda; Michael Miller; Marc Witmer; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

6.  Defining the DNA substrate binding sites on HIV-1 integrase.

Authors:  James Dolan; Aiping Chen; Irene T Weber; Robert W Harrison; Jonathan Leis
Journal:  J Mol Biol       Date:  2008-11-07       Impact factor: 5.469

Review 7.  Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids.

Authors:  Vasu Nair; Maurice Okello
Journal:  Molecules       Date:  2015-07-13       Impact factor: 4.411

8.  Synthesis, crystal structure, DFT studies and biological activity of (Z)-3-(3-bromophenyl)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxyprop-2-en-1-one.

Authors:  Said Tighadouini; Redouane Benabbes; Monique Tillard; Driss Eddike; Khadija Haboubi; Khalid Karrouchi; Smaail Radi
Journal:  Chem Cent J       Date:  2018-11-26       Impact factor: 4.215

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.